Florian Lordick

Florian Lordick

Auto-generated profile, based on publicly available information

Florian Lordick

10Klinikum rechts der Isar, 3rd Medical Department, Technische Universität München, Ismaninger Straße 22, 81675 München, Germany

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 December 2011 in BMC Cancer
Verified
Journal Article
Open access
PDF file
BLBirgit Luber
Birgit Luber
JDJoëlle Deplazes
Joëlle Deplazes
GKGisela Keller
Gisela Keller
AWAxel Walch
Axel Walch
SRSandra Rauser
Sandra Rauser
FLFlorian Lordick
Florian Lordick
The activity of the epidermal growth factor receptor (EGFR)-directed monoclonal antibody cetuximab combined with oxaliplatin/leucovorin/5-fluorouracil (FUFOX) was assessed in first-line metastatic gastric and oesophago-gastric junction (OGJ) cancer in a prospective phase II study showing a promising objective tumour response rate of 65% and a low mutation frequency of KRAS (3%). The aim of the correlative tumour tissue studies was to investigate the relationship between EGFR gene copy numbers, activation of the EGFR pathway, expression and mutation of E-cadherin, V600E BRAF mutation and clinical outcome of patients with gastric and OGJ cancer treated with cetuximab combined with FUFOX.